Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Akrevia Therapeutics

Akrevia Therapeutics
2015 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$60.3M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of the next generation of cancer immunotherapies intended to discover and develop better, safer immunotherapeutics. The company's proprietary platform helps to produce cancer immunotherapies that are specifically activated in the local environment of the cancer and achieves precise targeting of therapeutic, enabling healthcare professionals to discover immune stimulating molecules and antibodies.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • LabCentral 610
  • 610 Main Street
  • Cambridge, MA 02139
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Akrevia Therapeutics’s full profile, request a free trial.

Akrevia Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 12-Dec-2019 $60.3M 000.00 Completed Product Development
2. Early Stage VC (Series A1) 27-Sep-2018 0000 000.00 Completed Product Development
1. Early Stage VC (Series A) 12-Oct-2016 $7.5M $7.5M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Akrevia Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
NS Investments Venture Capital Minority 000 0000 000000 0
Atlas Venture Venture Capital Minority 000 0000 000000 0
Eight Roads Venture Capital Minority 000 0000 000000 0
F-Prime Capital Partners Venture Capital Minority 000 0000 000000 0

Akrevia Therapeutics Executive Team (7)

Name Title Board
Seat
Contact
Info
Renee Russo Ph.D Chief Executive Officer
Timothy Clackson Ph.D President & Executive Vice President of Research & Development
John Williams Ph.D Scientific Co-Founder and Member of Scientific Advisory Board
Ulrich Rodeck Ph.D Scientific Co-Founder & Member of Scientific Advisory Board
Margret Karow Ph.D Senior Vice President, Preclinical Development

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

Akrevia Therapeutics Board Members (10)

Name Representing Role Since Contact
Info
Benjamin Auspitz Akrevia Therapeutics Board Member 000 0000
David Grayzel MD Atlas Venture Board Member 000 0000
Jessica Alston Ph.D F-Prime Capital Partners Board Observer 000 0000
Michael Gladstone Atlas Venture Board Member 000 0000
Nessan Bermingham Ph.D Atlas Venture Chairman 000 0000

3 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »